Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Axial Biotherapeutics is raising $10,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, David Donabedian played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders.

To learn more about Axial Biotherapeutics, visit http://www.axialbiotherapeutics.com/

Contact:
David Donabedian, Chief Executive Officer
617-874-5260
david@axialbiotherapeutics.com
https://www.linkedin.com/in/david-h-donabedian-73050a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved